Perspective Therapeutics Energizes Radiopharma with Promising Alpha-Particle Therapy for Neuroendocrine Tumors

Seattle-based Perspective Therapeutics shared promising early trial results at ASCO25 for its lead radiopharmaceutical therapy, [212Pb]VMT-α-NET, which targets neuroendocrine tumors. The drug uses a radioactive lead compound to deliver high-energy alpha particles directly to tumors, showing a 50% response rate in a small trial, much higher than the typical 13%. Perspective’s therapy aims to stay localized in tumors, unlike other treatments that spread more widely in the body.